Dacomitinib/Dacomitinib production place and country of origin information

Dacomitinib/Dacomitinib (Dacomitinib) is an oral small molecule targeted drug developed and produced by Pfizer, an internationally renowned pharmaceutical company. Pfizer is headquartered in the United States. As a leading innovative pharmaceutical company in the world, its R&D capabilities and production standards are highly recognized internationally. Dacomitinib is a second-generation irreversible EGFR inhibitor and one of Pfizer's core products developed for patients with advanced or metastatic non-small cell lung cancer (NSCLC). Its research and development process strictly follows international drug research and development standards, including preclinical research, clinical trials, and drug registration and approval.

The production of original drugs is mainly concentrated in the United States and Pfizer's certified factories in Europe and Asia. These factories implement full-process supervision in accordance with internationalGMP (Good Manufacturing Practice), from raw material procurement, production technology, quality control to packaging and delivery, to ensure that drug ingredients, dosage and purity meet strict standards. When exporting to different countries and regions, Pfizer will adjust packaging and labeling according to the registration requirements of the local drug administration, but the core ingredients and production batches of the drug will maintain the consistency of the original research to ensure that efficacy and safety are not affected.

In China, dacomitinib enters the market through formal import channels and is subject to approval and registration by the National Medical Products Administration (NMPA). Duozerun sold in China still maintains the standards of the original drug, and the drug ingredients, dosage and quality control fully meet the requirements of the original drug. When purchasing, patients can confirm their originator identity through the drug packaging, approval number, and import registration information to avoid the risk of counterfeit drugs.

Generally speaking, the country of origin of dacomitinib is the United States, and it is developed and produced by Pfizer. Its global production and quality management system ensures the efficacy and safety of the drug in domestic and foreign markets, providing reliable treatment guarantee for lung cancer patients.

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro